Anteris Technologies Global (NASDAQ:AVR) Stock Price Target Lowered at Barclays

Anteris Technologies Global (NASDAQ:AVR) had its price objective lowered by Barclays from $10.00 to $9.00 in a report published on Friday,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other research analysts have also recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Anteris Technologies Global currently has an average rating of “Hold” and an average price target of $13.75.

Anteris Technologies Global Stock Performance

Shares of AVR opened at $5.42 on Friday. The stock has a fifty day moving average price of $6.96 and a two-hundred day moving average price of $7.38. Anteris Technologies Global has a 52-week low of $3.30 and a 52-week high of $11.06. The company has a market cap of $528.40 million, a price-to-earnings ratio of -3.37 and a beta of 2.02.

Anteris Technologies Global (NASDAQ:AVR) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.75 million. Anteris Technologies Global had a negative return on equity of 57.15% and a negative net margin of 4,637.48%. As a group, research analysts predict that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insider Transactions at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of Anteris Technologies Global stock in a transaction on Monday, October 5th. The shares were purchased at an average price of $7.51 per share, with a total value of $4,869,897.05. Following the acquisition, the insider owned 12,778,380 shares in the company, valued at $95,965,633.80. This represents a 5.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders acquired 1,554,730 shares of company stock worth $11,694,513. 4.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Anteris Technologies Global

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Anteris Technologies Global during the second quarter valued at $78,000. Bartlett & CO. Wealth Management LLC boosted its holdings in Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after acquiring an additional 8,200 shares during the last quarter. Greenline Wealth Management LLC acquired a new stake in Anteris Technologies Global in the third quarter worth about $88,000. Cetera Investment Advisers increased its position in Anteris Technologies Global by 64.7% in the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock worth $92,000 after purchasing an additional 6,500 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in Anteris Technologies Global in the third quarter worth about $93,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.